AZNAstraZenecaRunning, no new patients
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
Hepatocellular Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 760 (final count)
- Started
- Mar 28, 2022
- Main results expected
- Feb 23, 2026
- Fully finished
- Feb 26, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) for Arm A vs Arm C
Measured over: Approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05301842 · record last updated 2026-10-16 · checked 2026-11-09 15:47 UTC